Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02193295 · ClinicalTrials.gov registry record · NA

Reversal of Lipid-Induced Insulin Resistance

A NA study of Insulin Resistance and NAFLD, sponsored by Yale University.

Recruiting
Registry status
NA
Development phase
250
Enrollment target
2
Study locations

NCT02193295 is a NA study of Insulin Resistance and NAFLD that is actively recruiting participants, run by Yale University. The registered enrollment target is 250 participants, roughly in line with the 243-participant average among 120 other Insulin Resistance trials with a reported enrollment target. The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02193295, a NA study of Insulin Resistance and NAFLD, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
NA
Development phase
250 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to examine whether weight reduction decreases intramyocellular (IMCL) and hepatic lipid content, and improves insulin sensitivity of muscle and fat tissue in people who are insulin resistant and have a family history of type 2 diabetes. Hepatic mitochondrial oxidation will be assesses using a 3 hour triple tracer study (D7 glucose, 3-13C lactate and 13C4 beta-hydroxybutyrate).

Conditions Studied

Interventions

  • BEHAVIORAL Caloric Restriction

Study Locations (2)

Connecticut

  • Magnetic Resonance Research Center (MRRC) - New Haven
  • Yale Center for Clinical Investigation HRU - New Haven

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2002-10
Est. Completion 2034-12
Phase NA

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT02193295

The ClinicalTrials.gov registry entry for NCT02193295 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 243-participant average among 120 other Insulin Resistance trials with a reported enrollment target. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Insulin Resistance appearing as the primary indexed condition, and to 1 intervention - of which Caloric Restriction is the first listed.

NCT02193295 reports 2 study locations spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT02193295 about?

NCT02193295 is a clinical study titled "Reversal of Lipid-Induced Insulin Resistance". The purpose of this study is to examine whether weight reduction decreases intramyocellular (IMCL) and hepatic lipid content, and improves insulin sensitivity of muscle and fat tissue in people who are insulin resistant and have a family history of type 2 diabetes. Hepatic mitochondrial oxidation w...

What is the current status of trial NCT02193295?

This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2002-10. Estimated completion is 2034-12.

What conditions does trial NCT02193295 study?

This clinical trial studies the following conditions: Insulin Resistance, NAFLD.

What interventions are being tested in trial NCT02193295?

The interventions under investigation include: Caloric Restriction (BEHAVIORAL).

Who is sponsoring clinical trial NCT02193295?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02193295 being conducted?

This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Insulin Resistance

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.